Tag Archives: Union for Affordable Cancer Treatment (UACT)

Update from India on Xtandi (Enzalutamide) for cancer treatment

In January 2016, KEI and the Union for Affordable Cancer Treatment petitioned the US the Department of Health and Human Services or the National Institutes of Health to use the federal government rights in the patents on the prostate cancer … Continue reading

Posted in Cancer, Drug prices, Patent, Uncategorized | Tagged , , , | Leave a comment

US asked not to pressurise India to reject cancer drug license

Source: Hindu An international organisation working for cancer-affected people has asked the Obama administration not to pressurise India to reject a compulsory license on a drug for a rare form of leukaemia, which would be a de facto endorsement of … Continue reading

Posted in Cancer, Compulsory Licensing, Out of Cycle Review (OCR), Special 301 report, US pressure on India, USTR 301 report | Tagged , | Leave a comment